Yahoo
NasdaqCM - Nasdaq Real Time Price USD

MIRA Pharmaceuticals, Inc. (MIRA)

0.5485 -0.0231 (-4.04%)
At close: October 30 at 4:00:01 PM EDT
0.5675 +0.0190 (+3.46%)
After hours: October 30 at 4:19:51 PM EDT
Chart Range Bar
Loading chart for MIRA
  • Previous Close 0.5716
  • Open 0.5890
  • Bid 0.5180 x 200
  • Ask 0.9373 x 200
  • Day's Range 0.5101 - 0.5890
  • 52 Week Range 0.5100 - 1.7500
  • Volume 207,648
  • Avg. Volume 610,026
  • Market Cap (intraday) 23.049M
  • Beta (5Y Monthly) 1.49
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1400
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 3.50

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

mirapharmaceuticals.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MIRA
63.68%
S&P 500 (^GSPC)
10.73%

1-Year Return

MIRA
66.76%
S&P 500 (^GSPC)
11.11%

3-Year Return

MIRA
73.37%
S&P 500 (^GSPC)
81.91%

5-Year Return

MIRA
92.16%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -1.21M
Profit Margin 0.00%

Q1

FY25

Q2

FY25

Q3

FY25

Q2

FY26

-2M
-1M
-500K
0
0.0%

Analyst Insights

View More

Analyst Price Targets

3.50
3.50 Average
0.5485 Current
3.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/17/2026
Analyst Maxim Group
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 3.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -129.55%

  • Return on Equity (ttm)

    -217.12%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -31.04M

  • Diluted EPS (ttm)

    -1.1400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.11M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.01M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: